records studied), the reaction rate was 5 9 per 1,000. In 1959 (20,687 records so far studied), the reaction rate was 9 96 per 1,000. How much of this apparent increase was due to a greater awareness of such reactions was not known.
M. Herold (Czechoslovakia) stated that aminopyrine, which had been found to raise the serum levels when given with benzyl penicillin, had failed to do so with phenoxymethyl penicillin (V). Ascorbic acid was remarkably successful in raising the serum levels two-to three-fold.
The first reports were available of the use of potassium alpha -phenoxy -methyl penicillin (BL P1 52), a combination of two diastereoisomeric forms sold commercially in the U.S.A., as "Syncillin" (6-alpha-phenoxy-propionamido-penicillanic acid). Following the work of J. C. Sheehan (U.S.A.) who first converted penicillin G to 6-aminopenicillanic acid (and synthesized penicillin V), and that of the English workers Doyle and Rolinson, who found an economic source of this compound in fermentation broths, it was apparent that the synthesis of innumerable new penicillin compounds was now possible. Over 500 had already been prepared by Bristol Laboratories, and, as reported by Dr. Welch in his opening address, by the manipulation of side-chains, broad spectrum, anti-fungal, anti-viral, and anti-tumour penicillins might be future chemical possibilities.
Penicillin P 152 had been made chemically by reacting alpha-phenoxypropionyl chloride with 6-amino-penicillanic acid obtained from broth. Four papers from the Bristol Laboratories, and two from other sources, reported that in animal protection tests this was consistently more active than penicillin G or V, that it had no irritant properties when administered intradermally, intramuscularly, or even intrathoracically, and that peak serum concentrations after oral administration were substantially higher than with comparable doses of penicillin V. Indeed, the dose-for-dose blood levels obtained with P 152 by mouth were similar to those obtained with benzyl penicillin G given intramuscularly.
Moreover The only antibiotic with which it could be mixed was streptomycin itself and attention had to be drawn to its toxic effect on the eighth nerve on the label of the package. There was scope for research in Great Britain into the extent of the aural damage which might have been caused by dihydrostreptomycin. As the deafness might not occur until some months had elapsed, the part played by the drug might not always be appreciated.
Reports from Portugal concerned the merthionates of streptomycin and dihydrostreptomycin; it was suggested that these might be less toxic than the sulphates.
Chloramphenicol
An analogue of chloramphenicol (Dextrosulphenidol) had been tested in vitro against the gonococcus by J. D. Thayer and associates (Chapel Hill, North Carolina), and compared with Kanamycin, Leucomycin, and chloramphenicol. The new analogue proved to be the most active. It was shown by W. Garson and associates (North Carolina) to be 8 to 32 times more effective in experimental syphilis than chloramphenicol. It was suggested that its toxic effects (haemopoietic) might be minimized in man by using much smaller doses.
Tetracycline
This had been used in doses of 1 g. daily for 3 months in cases of chronic bronchitis by P. S. Norman and colleagues (John Hopkins Hospital, Baltimore). Benefit was shown in 21 of 39 treatments with tetracycline compared with eleven of 39 treatments with a placebo. J. C. Murdoch (Royal Infirmary, Edinburgh) described a double-blind trial in which oxytetracycline (1 g. daily) or dummy tablets were given over a 6-month period for the same condition. Of the forty patients receiving dummies, 27 were off work for 358 days during the winter, whereas 23 of the 26 patients who completed the full course of active treatment remained at work, and the whole series of 35 patients in the treated group were off work for 210 days.
0. De Veiga (Brazil) had studied the effect of oxytetracycline on the growth and weight of children. Those receiving 50 mg. daily over a 4-month period increased by 37-41 per cent. in weight and by 37-41 per cent. in height more than the controls.
As with penicillin, a significant advance had occurred with the tetracyclines. The addition of a CH3 group to penicillin V had increased its absorbability. The deletion of a similar group from chlortetracycline had accomplished a similar improvement. Already a confusing array of tetracycline preparations was on the market. They were based on chlortetracycline, oxytetracycline, and tetracycline itself, with their subsequent potentiation by means of citric acid, the phosphate complex, cosamine, and other means.
A new derivative developed by Lederle, dimethylchlortetracycline (DMCT), was being sold as "Declomycin" within the U.S.A. and Canada and as "Ledermycin" elsewhere. DMCT had been found to produce higher and more persistent blood levels than either chlortetracycline or oxytetracycline, and was excreted only 43 per cent. as fast as tetracycline; significant serum levels were present 48 to 72 hours longer than after tetracycline. Susceptibility tests on over 850 strains of fifteen bacterial pathogens were reported by M. Finland (Boston). The new drug was reported not only to have a similar range to other tetracyclines but also to have proved effective against some strains which were resistant to the tetracyclines. L. P. Garrod (London) reported that DMCT was twice as active as tetracycline against some organisms; given to 48 medical students it was well tolerated and the number of bowel actions (1 -4 per day) were no more than with other tetracycline preparations.
Many reports were presented concerning its use in pneumonia, brucellosis, urinary tract infections, gonorrhoea, bacillary dysentery, and dermatological conditions. M. Marmell and A. Prigot (New York) reported that in gonorrhoea the required dose (600 mg. over 1-2 days) was almost as small as the required dose of tetracycline by injection. All but two of 62 patients were cured. In view of its greater powers it was supplied in capsules of only 125 mg. which might be given two to four times a day instead of the 250 mg. four times a day which was needed for the older established tetracyclines. Sideeffects were few in patients treated with 10 mg./kg., but vomiting and nausea occurred in some persons given 15 mg./kg. body weight or more.
Another tetracycline compound described was pyrrolidinomethyl tetracycline. Papers (Germany) reported that the resistance figure to M. pyogenes was 20 per cent. The combination had been used by M. S. Greif (Austria) in the treatment of cholecystitis and negative bile cultures were obtained in 78 out of eighty patients after 4 to 5 days. Other workers reported its successful use in "pneumonopathies", upper respiratory infections in children, serious surgical staphylococcal infections, intestinal amoebiasis, gynaecological infections, and syphilis.
Few data were presented concerning antibiotic/ steroid combinations, but J. Kirby and associates (Washington) had conducted a controlled blind study of 42 patients with pneumonia; 33-3 per cent. were afebrile 24 hours after therapy when tetracycline alone was used, and 72-2 per cent. when steroids were given in addition.
Anti-Fungal Antibiotics
Systemic fungal disease seemed to be a greater problem in the U.S.A. than in Britain. Amphotericin B had proved life-saving in these serious disorders. G. L. Baum (Cincinatti) had used the antibiotic in six cases of histoplasmosis, five of North American blastomycosis, and two of cryptococcosis. One of the histoplasmosis patients died of lung cancer, -but the others were well 3 to 18 months after treatment. The antibiotic may produce undesirable and sometimes grave side-effects. C. C. Campbell (Washington) noted that, although previously reported as ineffective when given orally, it would prolong the survival time in animals suffering from the abovementioned diseases when given in the drinking water. It is also active in Leishmaniasis.
A special symposium on Griseofulvin had taken place in Havana a few weeks earlier. This antibiotic was active orally against a variety of fungi associated with dermatophytosis in man and animals. H. Behrman and associates (New York) treated 97 children with tinea capitis, and negative culturzs were obtained 4 to 13 weeks after therapy. N. J. Goldfarb (New York) found griseofulvin of definite use in the treatment of tinea cruris which responded rapidly, 1 g. daily being the usual dose. It would cause some gastric distress in some patients and instances of psychic stimulation had been reported.
Anti-Tuberculous Drugs
Sulphasoxizole and sulphadimethoxine had proved to be tuberculostatic in guinea-pigs. A new phenyl-PAS and also the use of Cycloserine were described.
Anti-Tumour Antibiotics
Experimental evidence, obtained within the last few years, indicated that certain antibiotics had strong anti-tumour effects on specific animal neoplasms. Studies of these drugs (called "Antimitotics" at a symposium held in Geneva earlier in 1959) might yield information applicable for possible trial against human cancer.
Kanematsu Sugiura (Sloan-Kettering Institute, New York) had tested 29 antibiotics against nineteen solid tumours in the mouse, seven in the rat, three in hamsters, three ascites tumours on the mouse, one mouse leukaemia, one mouse virus leukaemia, and one chicken tumour. The first intra-peritoneal injection of the antibiotics at maximum tolerated doses was given 1 to 7 days after tumour transplantation and injections were continued for 7 days. Mitomycin C was possibly the most effective antibiotic tested, and was followed by Fumagillin, 6-diazo-5-oxy-L-norleucine, the actinomycins, actinobolin, sarkomycin, and streptovitacin A. Mitomycin C, which had been used on 663 malignant cases in 1958 in Japan, was described by Yaemon Shiraha and colleagues (Osaka, Japan). Of 194 cases treated, the disease was inoperable in 151 and the 43 others were given Mitomycin C postoperatively to prevent relapse. Three patients with advanced malignancy (maxilla, bladder, stomach) were well 10 to 20 months after starting treatment, as were 24 of 27 cases treated prophylactically. Other work on humans concerned Cyclophosphamide (Cytoxan), which was given to ten children with various types of tumour by H. G. Crambleet (Iowa). Remission for 3 to 5 months were noted in two cases of lymphoma, one of rhabdomyosarcoma, and one of Hodgkin's disease, and haematological improvement was noted in two leukaemic patients. Toxic complications included leukopenia and alopoecia.
Two new anti-tumour agents-Streptonigrin and the diazomycins-were described. These had been tested by Koppaka Rao 
Laboratory Methods
In one of a number of papers on antibiotic sensitivity-testing, A. Branch (Canada), having tested penicillin-sensitivity disks from the U.S.A., Canada, and Europe, concluded that there was a pressing need for standardization of methods and interpretation and of disk concentrations, so that a proper exchange of information and understanding could take place on a national and international scale. This plea was echoed by T. G. Anderson (Philadelphia).
The introduction of automation into turbidimetric assays was reported by D. M. Hucke (Pfizer Laboratories, New York). Using two spectrophotometers, a digital voltmeter, and IBM equipment, a system has been developed which automatically recorded light-transmission readings on punch cards, which were fed into the computer in which the test results were calculated, and then returned to the laboratory for reporting.
